Senolytics reduce COVID-19 symptoms in preclinical studies

Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates the damaging impact of senescent cells in the body. In preclinical studies, the senolytic drugs discovered at Mayo significantly reduced inflammation, illness, and mortality from COVID infection in older mice. The findings appear in the journal Science.